Harel Insurance Investments & Financial Services Ltd. Takes $35,000 Position in ZIOPHARM Oncology Inc. (ZIOP)

Harel Insurance Investments & Financial Services Ltd. acquired a new position in shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 9,000 shares of the biotechnology company’s stock, valued at approximately $35,000.

Several other hedge funds have also made changes to their positions in the stock. MSD Partners L.P. lifted its position in shares of ZIOPHARM Oncology by 222.1% during the 4th quarter. MSD Partners L.P. now owns 10,986,258 shares of the biotechnology company’s stock worth $20,544,000 after buying an additional 7,575,758 shares during the last quarter. BlackRock Inc. lifted its position in shares of ZIOPHARM Oncology by 1.3% during the 3rd quarter. BlackRock Inc. now owns 9,289,620 shares of the biotechnology company’s stock worth $29,727,000 after buying an additional 121,880 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of ZIOPHARM Oncology by 2.3% during the 3rd quarter. Vanguard Group Inc. now owns 8,783,696 shares of the biotechnology company’s stock worth $28,108,000 after buying an additional 194,441 shares during the last quarter. Vanguard Group Inc lifted its position in shares of ZIOPHARM Oncology by 2.3% during the 3rd quarter. Vanguard Group Inc now owns 8,783,696 shares of the biotechnology company’s stock worth $28,108,000 after buying an additional 194,441 shares during the last quarter. Finally, Northern Trust Corp lifted its position in shares of ZIOPHARM Oncology by 0.5% during the 4th quarter. Northern Trust Corp now owns 1,647,754 shares of the biotechnology company’s stock worth $3,081,000 after buying an additional 8,068 shares during the last quarter. Institutional investors and hedge funds own 38.01% of the company’s stock.

ZIOPHARM Oncology stock opened at $4.07 on Friday. The stock has a market capitalization of $660.54 million, a price-to-earnings ratio of -8.48 and a beta of 2.63. ZIOPHARM Oncology Inc. has a 12 month low of $1.56 and a 12 month high of $5.00.



ZIOPHARM Oncology (NASDAQ:ZIOP) last posted its earnings results on Tuesday, March 5th. The biotechnology company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.03. On average, equities research analysts anticipate that ZIOPHARM Oncology Inc. will post -0.32 EPS for the current fiscal year.

ZIOP has been the subject of several recent analyst reports. BidaskClub upgraded ZIOPHARM Oncology from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, March 20th. Laidlaw initiated coverage on ZIOPHARM Oncology in a research report on Monday, April 1st. They set a “buy” rating and a $7.50 price objective for the company. Finally, Lake Street Capital initiated coverage on ZIOPHARM Oncology in a research report on Thursday, April 4th. They issued a “buy” rating and a $7.00 target price for the company. One analyst has rated the stock with a sell rating, two have given a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. ZIOPHARM Oncology currently has an average rating of “Buy” and a consensus target price of $5.85.

TRADEMARK VIOLATION WARNING: “Harel Insurance Investments & Financial Services Ltd. Takes $35,000 Position in ZIOPHARM Oncology Inc. (ZIOP)” was posted by Dakota Financial News and is the property of of Dakota Financial News. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://dakotafinancialnews.com/2019/04/21/harel-insurance-investments-financial-services-ltd-takes-35000-position-in-ziopharm-oncology-inc-ziop.html.

ZIOPHARM Oncology Company Profile

ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells.

See Also: Call Option

Institutional Ownership by Quarter for ZIOPHARM Oncology (NASDAQ:ZIOP)

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.